[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-138442-105":59,"doc-detail-138442-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optimization-of-tools-for-monitoring-evaluating-and-treating-inflammatory-conditions-of-the-bowel","Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel","","Crohn’s disease and ulcerative colitis are the two main inflammatory bowel diseases, causing substantial long-term morbidity despite improved therapies. The thesis also addresses immune checkpoint inhibitor-induced enterocolitis, a distinct immune-mediated condition arising as a treatment side-effect. The aim is to generate new knowledge to monitor, evaluate, and treat inflammatory bowel conditions with a focus on IBD and IMC, including evaluation of targeted therapy use, non-medical switching strategies, and development of an endoscopic assessment tool.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optimization-of-tools-for-monitoring-evaluating-and-treating-inflammatory-conditions-of-the-bowel/138442/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optimization-of-tools-for-monitoring-evaluating-and-treating-inflammatory-conditions-of-the-bowel/138442.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-19","2026-08-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What conditions are the thesis primarily focused on?","Question",{"text":112,"@type":113},"The thesis focuses on inflammatory bowel disease, particularly Crohn’s disease and ulcerative colitis, and on immune checkpoint inhibitor-induced enterocolitis (immune-mediated enterocolitis, IMC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was investigated in Paper I?",{"text":117,"@type":113},"Paper I evaluated off-label use of the anti-α4β7 integrin inhibitor vedolizumab for IMC in patients treated with ipilimumab or nivolumab for metastatic melanoma or lung cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What did Paper IV contribute to clinical assessment?",{"text":121,"@type":113},"Paper IV developed the Simple Endoscopic Score for Ulcerative Colitis (SES-UC), based on vascular pattern and ulcers, designed to be simple to use while maintaining performance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},138442,1787481155,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":144},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel  \nBergqvist, Viktoria  \n2024  \nDocument Version:  \nPublisher's PDF, also known as Version of record  \nLink to publication  \nCitation for published version (APA):  \nBergqvist, V. (2024) . Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel. [Doctoral Thesis (compilation), Department of Clinical Sciences, Lund] . Lund University, Faculty of Medicine.  \nTotal number of authors: 1  \nGeneral rights  \nUnless other specific re-use rights are stated the following general rights apply:  \nCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.  \n• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.  \n• You may not further distribute the material or use it for any profit-making activity or commercial gain  \n• You may freely distribute the URL identifying the publication in the public portal  \nRead more about Creative commons licenses: [https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)  \nTake down policy  \nIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.  \nDownload date: 23. Aug. 2026  \nOptimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel  \nVIKTORIA BERGQVIST  \nDEPARTMENT OF CLINICAL SCIENCES | FACULTY OF MEDICINE | LUND UNIVERSITY  \nOptimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel  \nOptimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel  \nViktoria Bergqvist  \nDOCTORAL DISSERTATION  \nDoctoral dissertation for the degree of Doctor of Philosophy (PhD) at the Faculty of Medicine at Lund University, Sweden. To be publicly defended on Friday, November 15th at 9 a.m. in Lilla Aulan, Jan Waldenströms Gata 5, Malmö  \nFaculty opponent  \nAssociate Professor Pontus Karling  \nDepartment of Public Health and Clinical Medicine, Umeå University  \nOrganization: LUND UNIVERSITY  \nDocument name: Doctoral dissertation  \nDate of issue: November 15, 2024  \nAuthor(s): Viktoria Bergqvist  \nTitle: Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel Abstract:  \nCrohn’s disease (CD) and ulcerative colitis (UC) are the two main types of inflammatory bowel disease (IBD) . The prevalence of these conditions is approximately 0.7% . With the advent of new treatments and improved management algorithms throughout the last century, the mortality rates associated with these conditions have decreased steeply. However, IBD is still a major cause of lifetime morbidity. Immune checkpoint inhibitor-induced enterocolitis, or immune-mediated enterocolitis (IMC), is a similar yet distinct condition that may arise as a side-effect to treatment with immune checkpoint inhibitors against various types of neoplasias. The main aim of this thesis work was to generate new knowledge on how to monitor, evaluate, and treat inflammatory conditions of the bowel with a focus on IBD and IMC.  \nIn paper I, we successfully evaluated off-label use of the anti-α4β7 integrin inhibitor vedolizumab for IMCin a cohort of patients treated with ipilimumab or nivolumab due to metastasized melanoma or lung cancer, respectively.  \nIn paper II, we investigated the impact of a non-medical switch from the originator infliximab to its biosimilar CT-P13 in a cohort of 313 IBD patients with a follow-up period of 12 months. Our results indicated that this type of switch was feasible with maintaned therapeutic effect and no new safety signals.  \nIn ","cbCaiopbEkO8I6Qa","https://ap.wps.com/l/cbCaiopbEkO8I6Qa","pdf",5548605,96,"English","# Background and aim\n## Inflammatory bowel disease and immune-mediated enterocolitis\n# Study aims and methods\n## Paper I: IMC treatment evaluation\n## Paper II: Switch from originator infliximab to biosimilar CT-P13\n## Paper III: Switch from intravenous to subcutaneous vedolizumab\n## Paper IV: Development of an endoscopic score for UC","[{\"question\":\"What conditions are the thesis primarily focused on?\",\"answer\":\"The thesis focuses on inflammatory bowel disease, particularly Crohn’s disease and ulcerative colitis, and on immune checkpoint inhibitor-induced enterocolitis (immune-mediated enterocolitis, IMC).\"},{\"question\":\"What was investigated in Paper I?\",\"answer\":\"Paper I evaluated off-label use of the anti-α4β7 integrin inhibitor vedolizumab for IMC in patients treated with ipilimumab or nivolumab for metastatic melanoma or lung cancer.\"},{\"question\":\"What did Paper IV contribute to clinical assessment?\",\"answer\":\"Paper IV developed the Simple Endoscopic Score for Ulcerative Colitis (SES-UC), based on vascular pattern and ulcers, designed to be simple to use while maintaining performance.\"}]","Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel | PDF",242]